Home
IDERHA
Improving clinical decision-making and enhancing patient access to health innovations through better use of health data.
IDERHA aims to build a scalable platform for a seamless integration or linkage of diverse real-world data at scale to support healthcare professionals, patients and researchers with new capabilities to improve lung cancer patients’ outcomes. We aim to do that by achieving better treatment and disease management, enabling personalized care, bolstering research innovation based on the development of common standards and practices. IDERHA will link and analyse, with artificial intelligence and machine learning, diverse human health data to improve early detection of lung cancer and the quality of life for individuals with experience with lung cancer. To enable patients and healthcare providers to benefit from novel health solutions, IDERHA seeks to accelerate policy development. Thereby, IDERHA aids regulatory approval and Health Technology Assessments (HTA).
33
partners
36M €
funding
5 years
duration
About IDERHA
In recent years, there has been an exponential growth in the generation of data that could be harnessed for use in healthcare delivery and research. These data include readouts generated by digital technologies, patient reported outcome and experience measures, and results from clinical trials and routine clinical care. However, accessing, integrating and analysing these data to maximize their value for patient care and research is extremely challenging.
The IDERHA (Integration of Heterogeneous Data and Evidence towards Regulatory and HTA Acceptance) project aims to create a scalable platform for the seamless integration or linkage of diverse data to support healthcare professionals, patients, and researchers with new capabilities to improve patient outcomes. The new platform will be based on the development of the common standards and practices – reducing current disconnected information silos. The enables more personalized health care along the patient’s journey via data-driven tools and solutions. The consortium will, therefore, develop the first pan-European health data space, and through policy recommendations drive health data access and the acceptability of heterogeneous health research results for regulatory and Health Technology Assessment decision-making.
IDERHA will focus on lung cancer, which is responsible for 20% of cancer-related death in Europe and one of the key priorities of the Europe Beating Cancer program. The project will link and analyse diverse data of a lung cancer patient’s journey: from early screening of citizens at risk, to development of lung cancer, to remote monitoring of late-stage patients to enable better care in an at home setting. Ultimately, the platform and policy recommendations will be disease independent.
To enable patients and health care providers to benefit from novel health solutions, IDERHA also seeks to accelerate policy development. Informed by patients needs, IDERHA will develop consensus recommendations for fully compliant health data access and sharing, as well as for the acceptability of heterogeneous health research results for regulatory and HTA decision-making. This may lead to a framework for data governance that can be used as a model globally.
IDERHA is a European public-private partnership funded by the EU Innovative Health Initiative (IHI), with representation from academic, clinical, medtech, pharmaceutical, IT and patient advocacy organizations as well as public authorities from across the EU and the world. IDERHA started April 1st, 2023 and will run for 5 years.
Learn more about the project on their website.
Lygature in IDERHA
Lygature will support IDERHA with over-all program management and project communications and dissemination, which will be important for IDERHA because of the large number of participants in the consortium. In this role, Lygature will benefit from extensive experience in previous multi-stakeholder collaborations such as the IMI European Lead Factory and APPROACH projects.
Next to this role, Lygature will also contribute specific data infrastructure expertise from its existing partnership in ongoing national and European projects. An important role in this domain will be to coordinate the data protection, compliance, and ethical framework.
Finally, Lygature will also get involved in the regulatory aspects of IDERHA, specifically for the ethical and transparent AI development within the project.
Lygature together with
Servicio Andaluz de Salud (ES); Fraunhofer-Gesellschaft (DE); Asklepios Kliniken (DE); DEFACTUM (DK); Danish Medicines Agency (DK); European Cancer Patient Coalition (EU); The European Patients’ Forum (EU); University of Applied Sciences Technikum Wien (AT); HULAFE (ES); The European Institute for Innovation through Health (EU); Ludwig Boltzmann Institute (AT); Servizo Galego de Saúde (ES); Klinikum Rechts der Isar (DE); Luxembourg Centre for Systems Biomedicine (LU); VTT Technical Research Centre of Finland (FI); Medical School Berlin (DE); Medical University of Vienna (AT); Janssen Pharmaceutica NV (BE); Janssen Vaccines & Prevention BV (US); Philips Medical Systems Nederland BV (NL); Labcorp early development Laboratories Limited (BE); Sanofi; Roche (CH); Johnson & Johnson MedTech (US); Takeda Pharmaceutical Company Limited (JP); Information Technology for Translational Medicine S.A. (LU); Q1.6 BV (BE); European Respiratory Society (EU); Hygiaso AG (CH); Lung Cancer Europe (EU); National Institute for Health and Care Excellence (UK); Fundacion Publica Andaluza Investigacion (ES);